Howard Horn - 01 Mar 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
Chief Financial Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
01 Mar 2026
Net transactions value
-$227,538
Form type
4
Filing time
03 Mar 2026, 18:50:25 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Horn Howard Chief Financial Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO /s/ Karah Parschauer, attorney-in-fact 03 Mar 2026 0001786335

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +6,143 +6.9% $0.000000 95,078 01 Mar 2026 Direct F1
transaction RARE Common Stock Sale $120,612 -5,290 -5.6% $22.80 89,788 02 Mar 2026 Direct F2, F3
transaction RARE Common Stock Sale $70,302 -3,119 -3.5% $22.54 86,669 02 Mar 2026 Direct
transaction RARE Common Stock Sale $36,624 -1,635 -1.9% $22.40 85,034 03 Mar 2026 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metric.
F2 Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.